Answer
Patients receiving trastuzumab emtansine are monitored for fever, chills and other infusion-related reactions during infusion and for at least 90 minutes after the initial infusion, and at least 30 minutes after subsequent infusions.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §4.2 Posology and method of administration · Version 18Document updated
Sources checked